Jane Street’s Immunome IMNM Stock Holding History

Jane Street’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-60,708	Closed	-$1.07M	–	11726
2025 Q3	$711K	Buy	+60,708	New	+$604K	﹤0.01%	7060
2025 Q1	–	Sell	-18,153	Closed	-$174K	–	9971
2024 Q4	$193K	Sell	18,153 -15,098	-45%	-$182K	﹤0.01%	8438
2024 Q3	$486K	Sell	33,251 -34,361	-51%	-$488K	﹤0.01%	7223
2024 Q2	$818K	Sell	67,612 -130,155	-66%	-$2.04M	﹤0.01%	6165
2024 Q1	$4.88M	Buy	197,767 +94,292	+91%	+$1.91M	﹤0.01%	2637
2023 Q4	$1.11M	Buy	+103,475	New	+$860K	﹤0.01%	5371

Other funds holding IMNM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Jane Street's IMNM Position: Q4 2025 in Review

Jane Street sold out of Immunome (IMNM) in Q4 2025, closing a stake of 60,708 shares — an estimated $1.07M sold.

Jane Street first reported a position in IMNM in Q4 2023 and held it in 6 quarters. The position peaked at $4.88M in Q1 2024. 182 funds tracked by Wall St. Rank hold IMNM as of Q4 2025.

Jane Street reported no remaining Immunome position as of Q4 2025 after selling out during the quarter.
Jane Street sold 60,708 Immunome shares in Q4 2025, an estimated $1.07M.
Jane Street first reported a position in Immunome in Q4 2023 and held it in 6 quarters.
Jane Street's Immunome position peaked at $4.88M in Q1 2024.
182 funds tracked by Wall St. Rank held Immunome as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.